Please login to the form below

Not currently logged in
Email:
Password:

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

Gilead Sciences

Gilead Sciences has settled a patent dispute with Teva over its HIV and hepatitis drug Viread ahead of a US court case to test the strength of its intellectual property.

No financial terms of the settlement have been disclosed, but according to a Gilead statement, Teva has agreed to hold off on launching a generic version of Viread (tenofovir disoproxil fumarate) until December 15, 2017, when the US patent on the drug expires.

The litigation between the two companies on the validity of Gilead's Viread patent had been due to come to trial later today in the District Court for the Southern District of New York.

Tenofovir disoproxil fumarate has been a massive success for Gilead since it first launched in 2001, both in the Viread brand and as a component of the company's combination treatments for HIV and hepatitis B.

Viread achieved sales of $850m last year. Meanwhile Gilead's entire antiviral franchise of five products - all of which contain the active ingredient - brought in $8.14bn out of total product sales of $9.40bn.

The deal also buys time for Gilead to bring its Viread follow-up tenofovir alafenamide fumarate (TAF) to market. TAF entered the phase III testing stage last year and has been designed to reduce some of the side effects of its parent compound including the risk of renal impairment and bone thinning.

"This settlement removes some uncertainty and minimises further distraction and investment of human and financial resources associated with this litigation," said Gilead's chief operating officer John Milligan in a statement.

Previously, Gilead has successfully defended its Viread patent estate in US court cases which took place in 2008 and 2010.

20th February 2013

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics